AUTHOR=Wang Eric , Chen Shali , Ali Anorin , Feng Biao , Liu Selina , Gonder John , Sheidow Tom , Hooper Phil , Chakrabarti Subrata TITLE=Use of serum long non-coding RNA expression panel as a marker for diabetic retinopathy JOURNAL=Frontiers in Cardiovascular Medicine VOLUME=Volume 12 - 2025 YEAR=2025 URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2025.1523997 DOI=10.3389/fcvm.2025.1523997 ISSN=2297-055X ABSTRACT=IntroductionDiabetic retinopathy (DR) is the most common chronic complication of diabetes, the leading cause of vision impairments in working-aged adults, and a significant cause of reduced quality of life for diabetic patients. Diabetic patients are recommended to have regular screening in order to catch DR at an early enough stage for effective management. However, due to a variety of factors, many patients can still fall through the cracks with the current screening methods.MethodsSeveral long non-coding RNAs (lncRNAs), essential regulators of physiological and pathological processes, were previously identified by us as potential markers for DR phenotypes. In this study, we used a significantly larger sample set to validate our panel of lncRNAs. We also explored the possibility of creating a statistical model to detect DR from serum samples using the expression profiles of these lncRNAs.ResultsOur regression models, based solely on lncRNA expression data, demonstrated the ability to adequately detect DR and potentially predict it. Models based solely on lncRNA expression performed equally or better compared to models with additional patient information. The models showed promising performance, suggesting that serum lncRNA expression profiles could serve as reliable markers for DR detection.DiscussionFurther longitudinal studies are necessary to validate the model's capability to predict retinopathy in diabetic patients not yet diagnosed with DR. Nevertheless, our findings indicate that this lncRNA panel may offer a viable option for a simple, accessible, and convenient blood-based screening test for DR.